A recent study introduced and clinically validated a drug response predictor (DRP) for dovitinib, a drug used to treat various cancers. This DRP tool, made up of 58 mRNA biomarkers, successfully identified a subset of patients with advanced renal cell carcinoma (RCC) who showed greater benefits from dovitinib treatment. Specifically, patients with a positive DRP had a median overall survival of 15 months compared with 9.13 months in those with a negative DRP. The tool also showed efficacy in predicting responses in other types of cancers like hepatocellular carcinoma. Before this DRP tool can be applied to patients with RCC treatments, a prospective trial is needed for further validation.
Reference: The ASCO Post Staff. New Data on a Response Biomarker for Dovitinib in Patients With RCC. The ASCO Post. Updated September 15, 2023. Accessed October 16, 2023. https://ascopost.com/news/september-2023/newly-published-data-on-a-response-biomarker-for-dovitinib-in-patients-with-rcc/
